NasdaqGS:ZBIOBiotechs
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Obexelimab Phase 3 Data And FDA BLA Submission
Clinical data and regulatory milestones in focus
Zenas BioPharma (ZBIO) stock is drawing attention after the company reported detailed Phase 3 INDIGO data for obexelimab in IgG4-Related Disease and advanced a Biologics License Application with the FDA.
See our latest analysis for Zenas BioPharma.
Despite the positive INDIGO data and recent Biologics License Application filing, Zenas BioPharma's share price has come under pressure, with the stock down 11.05% over 30 days and 49.36% year to...